期刊名称：Egyptian Journal of Pediatric Allergy and Immunology
印刷版ISSN：1687-1642
电子版ISSN：2314-8934
出版年度：2013
卷号：11
期号：1
页码：49-50
出版社：Egyptian Society of Pediatric Allergy and Immunology
摘要：This parameter was developed by the Joint Task Force on Practice Parameters, representing the AmericanAcademy of Allergy, Asthma & Immunology (AAAAI); the American College of Allergy, Asthma &Immunology (ACAAI); and the Joint Council of Allergy, Asthma and Immunology. Since the last parameteron AD was published in 2004, there have been remarkable advances in the understanding of the genetics andpathophysiology of the disease. Hypotheses on the cause of AD must now include epidermal barrier defects,as well as immune dysregulation of both the innate and adaptive immune systems. AD is a complexinflammatory process, our understanding of which is constantly undergoing revision as more data becomeavailable on the role of IgE-bearing Langerhans cells, atopic keratinocytes, monocytes/macrophages,eosinophils, and mast cells and their interaction with IL-4–, IL-5–, and IL-13–producing TH2, regulatory T,and TH22 lymphocytes. There is a complicated interaction between these cells and their products andsusceptibility genes and the host environment, which leads to the clinical findings that characterize AD. Themajor objective of this parameter is to improve the care of patients with AD. This should be accomplished byestablishing boundaries for the evaluation and management of patients with this condition while reducingunwanted and unnecessary variation in treatment
